# Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction

> **NCT01360086** · PHASE2 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 65 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** cisplatin
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** quality-of-life assessment
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT01360086
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2016-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01360086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01360086, "Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01360086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*